Profile data is unavailable for this security.
About the company
Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer. The Company has eight primary drug and AI technology programs: AL-101, an intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson’s Disease (PD), erectile dysfunction (ED) and female sexual dysfunction (FSD); CA4P, a vascular disrupting agent (VDA) in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma; Oxi4503, a second generation VDA for the treatment of liquid tumors with focus on childhood leukemia; OT-101, an antisense against TGF-β2 for the treatment of various cancers and viruses, including SARS and the COVID-19, and Artemisini, a natural derivative from an Asian herb Artemisia Annua that inhibits the ability of various viruses to multiply.
- Revenue in USD (TTM)70.00k
- Net income in USD-7.79m
- Incorporated1992
- Employees22.00
- LocationOncotelic Therapeutics Inc29397 Agoura Road Suite 107AGOURA HILLS 91301United StatesUSA
- Phone+1 (650) 635-7000
- Fax+1 (650) 635-7001
- Websitehttps://www.oncotelic.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Edesa Biotech Inc | 0.00 | -7.25m | 13.93m | 16.00 | -- | 3.22 | -- | -- | -2.37 | -2.37 | 0.00 | 1.34 | 0.00 | -- | -- | 0.00 | -84.50 | -- | -107.87 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 52.28 | -- | -- | -- |
| CERo Therapeutics Holdings Inc | 0.00 | -2.54m | 14.01m | 8.00 | -- | -- | -- | -- | -0.3796 | -0.3796 | 0.00 | -0.9226 | 0.00 | -- | -- | 0.00 | -9.96 | -- | -33.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -279.82 | -- | -- | -- |
| Vicapsys Life Sciences Inc | 0.00 | -1.08m | 14.24m | 2.00 | -- | -- | -- | -- | -0.0327 | -0.0327 | 0.00 | -0.0416 | 0.00 | -- | -- | 0.00 | -364.66 | -- | -- | -- | -- | -- | -- | -- | -- | -10.40 | -- | -- | -- | -- | -317.25 | -- | -- | -- |
| Microbot Medical Inc | 0.00 | -10.26m | 14.40m | 22.00 | -- | 2.33 | -- | -- | -0.8926 | -0.8926 | 0.00 | 0.4283 | 0.00 | -- | -- | 0.00 | -151.13 | -53.28 | -183.85 | -62.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18.44 | -- | -31.76 | -- |
| Traws Pharma Inc | 226.00k | -18.16m | 14.52m | 16.00 | -- | 2.01 | -- | 64.26 | -0.8641 | -0.8641 | 0.0108 | 0.2853 | 0.0085 | -- | 12.91 | 14,125.00 | -68.21 | -63.43 | -104.99 | -85.72 | -- | -- | -8,033.63 | -3,257.92 | -- | -- | 0.00 | -- | 0.00 | -28.72 | 0.0844 | -- | -- | -- |
| Mannatech Inc | 127.23m | -1.66m | 14.60m | 213.00 | -- | 1.40 | -- | 0.1147 | -0.899 | -0.899 | 68.07 | 5.54 | 2.77 | 1.93 | 561.74 | 597,342.80 | -3.62 | 4.39 | -9.67 | 9.16 | 78.01 | 77.87 | -1.31 | 1.72 | 0.5584 | -- | 0.1384 | 88.33 | -3.83 | -5.33 | 50.13 | -- | -20.38 | -- |
| Flora Growth Corp | 74.78m | -47.58m | 14.74m | 97.00 | -- | 3.29 | -- | 0.1971 | -6.53 | -7.77 | 9.20 | 0.3494 | 1.48 | 5.99 | 23.05 | 770,958.80 | -92.50 | -- | -140.01 | -- | 21.72 | -- | -62.66 | -- | 0.6481 | -- | 0.4952 | -- | 127.75 | -- | -1.87 | -- | -- | -- |
| Oncotelic Therapeutics Inc | 70.00k | -7.79m | 14.83m | 22.00 | -- | 1.25 | -- | 211.83 | -0.0197 | -0.0197 | 0.0002 | 0.0296 | 0.0021 | -- | 3.61 | 3,181.82 | -24.46 | -25.03 | -49.25 | -48.76 | -- | -- | -11,536.00 | -1,692.93 | -- | -0.4696 | 0.5341 | -- | -- | -- | -255.12 | -- | -- | -- |
| Inhibitor Therapeutics Inc | 0.00 | -3.17m | 15.10m | 3.00 | -- | 3.25 | -- | -- | -0.0184 | -0.0184 | 0.00 | 0.0269 | 0.00 | -- | -- | 0.00 | -34.05 | 27.48 | -34.48 | 32.70 | -- | -- | -- | -- | -- | -- | 0.00 | 0.00 | -- | -- | -125.39 | -- | -- | -- |
| Chemomab Therapeutics Ltd - ADR | 0.00 | -19.34m | 15.21m | 20.00 | -- | -- | -- | -- | -26.80 | -26.80 | 0.00 | -- | 0.00 | -- | -- | 0.00 | -72.94 | -- | -92.90 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 12.39 | -- | -- | -- |
| Tonix Pharmaceuticals Holding Corp | 10.25m | -98.59m | 15.56m | 103.00 | -- | 0.111 | -- | 1.52 | -5.54 | -5.54 | 0.2956 | 1.47 | 0.0652 | -- | -- | 99,514.56 | -62.71 | -59.46 | -70.20 | -65.92 | 37.55 | -- | -961.87 | -5,126.73 | 0.8666 | -- | 0.0767 | -- | -- | -- | 0.1874 | -- | 320.57 | -- |
| Trinity Biotech plc (ADR) | 56.71m | -33.88m | 15.62m | 380.00 | -- | -- | -- | 0.2754 | -4.42 | -2.81 | 7.41 | -14.96 | 0.625 | 1.69 | 3.67 | 149,229.00 | -37.34 | -20.30 | -47.55 | -29.54 | 34.21 | 39.92 | -59.75 | -29.86 | 1.03 | -1.96 | 1.36 | -- | -9.10 | -10.15 | 15.41 | -- | -31.08 | -- |
| Cardio Diagnostics Holdings Inc | 33.00k | -11.51m | 15.71m | 7.00 | -- | 4.93 | -- | 476.19 | -0.8257 | -0.8257 | 0.0021 | 0.1404 | 0.0051 | -- | -- | 4,714.29 | -178.70 | -- | -325.81 | -- | -- | -- | -34,872.12 | -- | -- | -4.84 | 0.0715 | -- | 1,696.84 | -- | -79.72 | -- | -- | -- |
